Abstract
Background: Matrix Metalloproteinases (MMPs) play an indispensable role in the initial alteration and development of PCa. We tried to generate an MMP-related prognostic signature (MMPS) in prostate cancer (PCa). Methods: TCGA-PRAD, MSKCC/GSE21032, GSE116918, GSE70769 cohorts were enrolled to assess the prognostic value of MMPs. The least absolute shrinkage and selection operator (LASSO) Cox regression was employed to generate the MMPS signature. The log-rank test and Kaplan-Meier (K-M) survival curve were applied to show the difference RFS, The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) was plotted to predict the accuracy of signature. CIBERSORT was conducted to analyze the different immune infiltration in MMPS-H and MMPS-L groups. Potential signaling pathways activated in the MMPS-H groups by Metascape. Results: MMP1, MMP7, MMP11, MMP24 and MMP26 were selected by LASSO regression and established the MMPS predict signature. The MMPS showed the high prognostic value in TCGA-PRAD training cohort (AUC=0.714) and validation cohorts (GSE116918: AUC=0.976, GSE70769: AUC=0.738, MSKCC: AUC=0.793). Pid integrin1 pathway, G2M checkpoint, and response to growth factor signaling pathways were activated in MMPS-H group, patients with the high MMPS risk score and low M2 macrophage showed the worst recurrence-free survival (RFS). Conclusion: MMPs involved and played an essential role in the tumorigenesis and biochemical recurrence in PCa patients. The MMPS signature could accurately predict the recurrence of PCa patients and validated in several cohorts.
Introduction
Prostate cancer (PCa) remains a leading cause of cancer-specific mortality in men globally. While many patients respond well to initial therapies like androgen deprivation, a significant portion eventually progresses to advanced stages or experiences biochemical recurrence. Matrix Metalloproteinases (MMPs) are zinc-dependent proteases known to degrade the extracellular matrix (ECM), essentially "clearing a path" for cancer cells to invade and metastasize. This study addresses the need for a collective, multi-gene signature that can reliably predict patient prognosis across different clinical datasets.
Methods
The researchers employed a multi-step computational approach utilizing several well-known public transcriptomic and clinical datasets, including TCGA-PRAD (496 patients) for training and MSKCC/GSE21032, GSE116918, and GSE70769 for validation.
Starting with 22 known MMPs, the team used LASSO (Least Absolute Shrinkage and Selection Operator) Cox regression to identify the most predictive candidates. This method is standard for high-dimensional data as it penalizes less important variables to zero, preventing overfitting and narrowing the selection to a robust five-gene signature: MMP1, MMP7, MMP11, MMP24, and MMP26.
Key Results and Insights
The established MMPS signature demonstrated high accuracy in predicting 1-year recurrence, with Area Under the Curve (AUC) values reaching 0.714 in the TCGA cohort and an impressive 0.976 in the GSE116918 cohort. Multivariate Cox analysis confirmed that the MMPS score is an independent predictor of recurrence, even when accounting for traditional clinical markers like Gleason score and pathological stage.
Analysis of the five specific genes revealed that MMP11 and MMP24 act as risk factors (higher expression correlates with worse outcomes), while MMP26 appeared to be protective in this context. Furthermore, the expression levels of these signature genes were found to correlate with pathological progression, showing significant differences between early (<=T2) and advanced (>=T3) stages.
Mechanistically, the study identified the COMP gene (Cartilage Oligomeric Matrix Protein) as a major downstream player associated with high risk scores. High-risk patients also showed activation of the Pid integrin1 pathway and G2M checkpoint. Interestingly, the study found a complex interplay with the immune microenvironment: patients with a high MMPS risk score combined with low M2 macrophage infiltration had the absolute worst recurrence-free survival, suggesting that matrix remodeling and immune evasion work in tandem to drive progression.
Conclusion
The MMPS signature is a robust tool for predicting recurrence in PCa patients. While the study is retrospective, the high AUC values across multiple cohorts suggest significant clinical potential. Future work should focus on prospective validation in real-world clinical settings and investigating the exact biochemical pathways through which these MMPs interact with the COMP gene to drive metastasis.
Summary updated